<DOC>
	<DOCNO>NCT01543087</DOCNO>
	<brief_summary>This study follow-up Pfizer study use rLP ( treatment assignment know ) investigational product ( treatment assignment unknown ) subject attend 6 study visit collection 20-mL blood sample visit .</brief_summary>
	<brief_title>Duration Immunity Study</brief_title>
	<detailed_description>Assess longevity immune response follow receipt 2 3 dos bivalent rLP2086 . The longevity immune response concomitant vaccination</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<criteria>1 . Evidence personally sign date informed consent document ( ICD ) indicate subject ( legal representative ) inform pertinent aspect study . 2 . Subjects willing able comply schedule visit , laboratory test , study procedure . 3 . Subjects complete primary study receive scheduled injection within originally plan schedule , either bivalent rLP2086 ( either 2 3 dos ) investigational product case subject vaccine assignment blind time consent study B1971033 . 4 . Subjects complete blood draw follow last vaccination subject complete 6month followup telephone call primary study . 1 . Subjects investigational site staff member directly involved conduct trial family member , site staff member otherwise supervised investigator , subject Pfizer employee directly involve conduct trial . 2 . With exception primary study bivalent rLP2086 , participation study within 1month ( 30day ) period study Visit 1 and/or study participation . Participation purely observational study permit . 3 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . 4 . History cultureproven disease cause N meningitidis Neisseria gonorrhoeae . 5 . Bleeding diathesis condition associate prolonged bleeding time would contraindicate blood draw . 6 . Receipt blood product , include gamma globulin , period 6 month study visit . 7 . Vaccination license experimental meningococcal serogroup B vaccine since enrol primary Pfizersponsored MnB study ( study vaccine permit primary study ) . 8 . Subjects compliant primary study eligibility criterion enrol primary study .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>